Tackling Counterfeit Drugs: The Challenges and Possibilities

被引:18
|
作者
Pathak, Ranjana [1 ]
Gaur, Vaibhav [2 ]
Sankrityayan, Himanshu [2 ]
Gogtay, Jaideep [2 ]
机构
[1] Dr Reddys Lab Ltd, Banjara Hills,8-2-337,Rd 3, Hyderabad 500034, Telangana, India
[2] Cipla Ltd, Global Med Affairs, Mumbai, India
关键词
PUBLIC-HEALTH; CONSEQUENCES; SUPPLEMENTS; COUNTRIES;
D O I
10.1007/s40290-023-00468-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drugs that have been manufactured or packaged fraudulently are referred to as counterfeit/fake/spurious/falsified drugs because they either lack active ingredients or have the incorrect dosages. Counterfeiting of drugs has become a global issue with which the whole world is grappling. The World Health Organization states the frightening figure in which almost 10.5% of the medications worldwide are either subpar or fake. Although developing and low-income countries are the targets of the large-scale drug counterfeiting activities, fake/substandard drugs are also making their way into developed nations including the USA, Canada, and European countries. Counterfeiting of drugs is leading to not only economic loss but is also playing its part in the morbidity and mortality of patients. The recent COVID-19 pandemic fuelled the demand for certain categories of medicines such as antipyretics, remdesivir, corticosteroids, vaccines, etc., thus increasing the demand and manufacture of subpar/fake medicines. This review articulates the current trends and global impact of drug counterfeiting, current and potential measures for its prevention and the role of different stakeholders in tackling the menace of drug counterfeiting.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 50 条